United Therapeutics (UTHR)
(Real Time Quote from BATS)
$235.42 USD
-1.58 (-0.67%)
Updated Apr 25, 2024 01:54 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
United Therapeutics (UTHR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$288.08 | $375.00 | $183.00 | 21.55% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for United Therapeutics comes to $288.08. The forecasts range from a low of $183.00 to a high of $375.00. The average price target represents an increase of 21.55% from the last closing price of $237.00.
Analyst Price Targets (12)
Broker Rating
United Therapeutics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 11 are Strong Buy, representing 78.57% of all recommendations. A month ago, Strong Buy represented 78.57%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
2/22/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/22/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
2/5/2024 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
11/2/2023 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
11/1/2023 | BTIG | Julian Harrison | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 14 |
Average Target Price | $288.08 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | 5.63 |